Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.PMID:34011260 | DOI:10.2174/1570163818666210519103001 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - May 20, 2021 Category: Drugs & Pharmacology Authors: Faraat Ali Kamna Sharma Varisha Anjum Asad Ali Source Type: research